Summary
Serdexmethylphenidate is a prodrug of dexmethylphenidate designed to provide extended therapeutic effects with reduced abuse potential through delayed onset. FDA-approved in 2021 as part of Azstarys for ADHD treatment in patients 6 years and older. The substance is metabolized in the lower gastrointestinal tract to release dexmethylphenidate gradually. Schedule IV controlled substance in the United States. Not recommended for patients with structural cardiac abnormalities, serious heart disease, or within 14 days of MAOI use.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 26.1mg(with5.2mgdexmethylphenidate) | - | - | - |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 1-2 hrs | 2-3 hrs | 4-8 hrs | 3-5 hrs |
Tolerance
Build-up
develops over days to weeks of regular use
Reset
3–7 days for acute tolerance; longer for full reset
Effects
Positive
- Stimulation
- Physical Euphoria
- Creativity Enhancement
Negative
- Increased heart rate
- Nausea
- Increased blood pressure
- Increased perspiration
- Vasoconstriction
- Sedation
- Difficulty urinating
Positive
- Focus enhancement
- Motivation enhancement
- Wakefulness
- Cognitive euphoria
- Analysis enhancement
- Cognitive Euphoria
Negative
- Anxiety
- Irritability
- Time distortion
- Time Distortion
Positive
- Tactile Enhancement
- Increased Music Appreciation
- Increased libido
- Pattern Recognition Enhancement
- Synaesthesia
Negative
- Appetite suppression
- Light sensitivity
- Auditory hallucination
- Dulled perception
- Auditory distortion